Localized prostate cancer detection with 18F FACBC PET/CT: Comparison with MR imaging and histopathologic analysis

Radiology

Volumn 270, Issue 3, 2014, Pages 849-856

  Turkbey, Baris ^a   Mena, Esther ^a   Shih, Joanna ^a   Pinto, Peter A ^a   Merino, Maria J ^a   Lindenberg, Maria L ^a   Bernardo, Marcelino ^a   McKinney, Yolanda L ^a   Adler, Stephen ^a   Owenius, Rikard ^b   Choyke, Peter L ^a   Kurdziel, Karen A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BIACORE AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCICLOVINE F 18;

ADULT; AGED; ANTERIOR CARDIAC COIL; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; ENDORECTAL COIL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; ROBOTICS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CARBOXYLIC ACIDS; CYCLOBUTANES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84895420876     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.13130240     Document Type: Article

References (25)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1):10-29.
2. Turkbey B, Albert PS, Kurdziel K, Choyke PL. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 2009;192(6):1471-1480.
3. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57(1):108-111.
4. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36(1):31-35.
5. Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K. The roles of PET and PET/CT in the diagnosis and management of prostate cancer. Oncology 2007;72(3-4):226-233.
6. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43(2):181-186.
7. 1H-MR spectroscopy. J Nucl Med 2010;51(11):1676-1683.
8. Mena E, Turkbey B, Mani H, et al. 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med 2012;53(4):538-545.
9. Bouchelouche K, Turkbey B, Choyke P, Capala J. Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep 2010;11(3):180-190.
10. 18F-fluorocyclobutyl- 1-carboxylic acid for the detection of prostate cancer. J Nucl Med 2007; 48(1):46-55.
11. 18F]1-amino-3-fluorocyclobutane- 1-carboxylic acid to image brain tumors. J Nucl Med 1999;40(2):331-338.
12. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007;48(1):56-63.
13. 18F-fluorocyclobutane- 1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 2011;259(3):852-861.
14. 18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging 2013;40(3):394-402.
15. 18)F] FACBC) uptake. Am J Nucl Med Mol Imaging 2013;3(1):85-96.
16. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007;48(3):471-480.
17. 18F]fluciclovine on a FASTlab synthesizer utilizing chemometric design [abstr]. J Nucl Med 2011;52(Suppl 1):1433.
18. 18F]FDG. J Labelled Comp Radiopharm 2012;55(3):97-102.
19. Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010;255(1):89-99.
20. Shah V, Pohida T, Turkbey B, et al. A method for correlating in vivo prostate magnetic resonance imaging and histopathology using individualized magnetic resonance-based molds. Rev Sci Instrum 2009;80(10):104301.
21. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16(5):834-840.
22. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5(4):584-590.
23. Liang KY, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 1986;73(1):13-22.
24. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999;281(15):1395-1400.
25. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235(2):623-628.